Abstract | AIM: METHODS: This study was a retrospective, six-center study conducted in Japan, in which 24 hemodialysis patients with HCV genotype 1-2 treated with glecaprevir/pibrentasvir were recruited. Blood examinations were performed at end of treatment (EOT), and at 3, 6, and 12 months post-treatment during the 12-month follow-up period. RESULTS: The overall sustained virologic response rate was 100% (24/24). During the DAA treatment period, adverse events were observed in 20.8% of patients (5/24), and pruritus was the most frequently observed in 12.5% (3/24). Interestingly, we observed an improved control of anemia after EOT with a significant increase in hemoglobin levels. In addition, total bilirubin was diminished, and platelet counts and albumin, total cholesterol, and alpha-fetoprotein levels remained unchanged after EOT in hemodialysis patients. Furthermore, erythropoietin concentration was not increased after EOT. CONCLUSIONS:
|
Authors | Asahiro Morishita, Chikara Ogawa, Akio Moriya, Joji Tani, Hirohito Yoneyama, Koji Fujita, Makoto Oryu, Tomonori Senoo, Koichi Takaguchi, Tsutomu Masaki |
Journal | Hepatology research : the official journal of the Japan Society of Hepatology
(Hepatol Res)
Vol. 50
Issue 5
Pg. 557-564
(May 2020)
ISSN: 1386-6346 [Print] Netherlands |
PMID | 31883211
(Publication Type: Journal Article)
|
Copyright | © 2019 The Japan Society of Hepatology. |